News Related to Phentolamine Ophthalmic Solution 0.75%

Related coverage linked through entity extraction aliases.

Opus Genetics Reports Progress in Gene Therapy Pipeline; Ultragenyx Announces Restructuring

Mar 10, 2026

Opus Genetics reported positive early data from its BEST1 gene therapy program and expects FDA action on its presbyopia treatment in October 2026. Ultragenyx announced 2025 revenue of $673 million and initiated a strategic restructuring plan targeting profitability in 2027.

FDA Accepts Viatris Presbyopia Treatment Application, Approves Rival Eye Drop Therapy

Feb 25, 2026

The FDA accepted Viatris' application for phentolamine ophthalmic solution 0.75% to treat presbyopia, with a decision expected October 2026. Separately, the agency approved Yuvezzi, a once-daily combination eye drop for age-related near vision loss.